The results suggest that increasing CFTR expression using dCas9-p300 may improve the efficacy of therapeutic modulators and contribute to the discovery of new therapeutic interventions for the treatment of cystic fibrosis (CF) (56); The dCas9-p300 platform is a powerful tool for studying acetylation modifications in biological processes, and some investigators have used dCas9-p300 or dCas9-HDAC8 fusion proteins to mimic or block acetylation induced by Fos gene enhancer activity to study how histone acetylation regulates Fos gene transcription through transient and rapid changes. This evidence concerns the gene HDAC8 and cystic fibrosis.